Zai Lab Ltd Stock News

Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET Company to Host Conference Call and Webcast on August 10, 2022, at 8:00 a.m. ET

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., July 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical

Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for gMG patients in China Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist

–   First company to Convert from Secondary to Primary Listing Status in Hong Kong

Commercial stage global biotech company Zai Lab (NASDAQ: ZLAB) stock has cratered (-82%) from a 52-week high of $178.91.

-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The top 3 positions are T-Mobile US, Amazon.com, and General Electric, together, at ~16% of the portfolio.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutica

Start Time: 08:00 January 1, 0000 8:48 AM ET Zai Lab Limited (NASDAQ:ZLAB ) Q1 2022 Earnings Conference Call May 11, 2022, 08:00 AM ET Company Participants Samantha Du - Founder, Chairperson and CEO B

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Acquires Biohaven For $11B Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold

- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardles

The group rose at least 300% in the pandemic before crashing 70% or more.

-- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET

-- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET